Resolutions of the Annual General Meeting for the Fiscal Year 2020/2021 of BRAIN Biotech AG
- Executive Board and Supervisory Board discharged by a large majority
- Shareholder majority approves capital reserve advance resolutions
- Positive outlook for the new fiscal year
At today's Annual General Meeting of BRAIN Biotech AG, the discharge of the Executive Board and Supervisory Board was approved by a large majority. All of the Annual General Meeting resolutions were passed by the participating shareholders, including the change of the auditor and a renewed advance capital reserve resolution to create flexible financing options for the future growth of the BRAIN Biotech AG.
Chief Executive Officer Adriaan Moelker emphasized with a view to the future: “The top priority for BRAIN Biotech AG remains our aim to become profitable. To achieve this, we will continue our drive for growth, control expenses, leverage synergies within the BRAIN Group and further optimize processes. We will continue to focus on our incubator pipeline and manage it systematically as communicated before. To help achieve our goals, we have defined clear responsibilities within the individual companies and throughout the Group. Hence, during the last two years we have created the conditions for profitable growth and we are confident that the BRAIN team will achieve our communicated ambitious goals.”
Chief Financial Officer Lukas Linnig summarized the development of the figures in the past fiscal year and stated: “The last quarter of the 2020/21 financial year showed a significant upturn in business activity despite the Corona pandemic. This positive trend has strongly continued in the first quarter of the new fiscal year. We currently have a solid cash position and aim to return to a stable growth path in financial year 2021/22. Our gene-editing technology platform, which we are currently developing, will be a major driver for this. We are on a very good path and have also expressed this in our quantitative full-year guidance.”
At the time of voting on the agenda items, between 10,153,716 and 13,918,524 of the capital stock divided into 21,847,495 registered shares were represented. The participation rate in voting, measured against the capital stock, was hence between 46.48% and 63.71%.
The detailed voting results as well as the presentations of the Management Board and all other documents relating to the Annual General Meeting are available on the BRAIN Biotech website at https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2020-21.
Press Image
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.